NI Formulary: Chapter 4 Central Nervous system

Similar documents
Medicines Formulary BNF Section 4 Central Nervous System

Chapter 4 ~ Central nervous system

Chapter 4 ~ Central nervous system

South London and the Maudsley NHS Foundation Trust Medicines Formulary

Chapter 4 Central Nervous System

Safe transfer of prescribing guidance

Chapter 4 Central Nervous System Answers. 1. What advice would you provide to someone who has just been initiated on Temazepam for insomnia?

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

APPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline

In our patients the cause of seizures can be broadly divided into structural and systemic causes.

Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Chapter 4 Central Nervous System

Chapter 4 Central Nervous System

BACKGROUND Measuring renal function :

Chapter 4 Central Nervous System

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary

Guide to the Long-Term Illness (LTI) Scheme

tablet/capsule Paracetamol 500mg

PARKINSON S MEDICATION

Appendix 2: Admissions checklists for people with Parkinson s

Berkshire West Area Prescribing Committee Guidance

Acute management of in-patient Parkinson s Disease patients

21 st June BDS BASHD Therapeutics Pain and Analgesia. BASHD Therapeutics Analgesics and Pain Management. Links to other BASHD content

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

A. Incorrect! Seizures are not typically linked to alcohol use. B. Incorrect! Epilepsy is a seizure that is commonly associated with convulsions.

BENZATROPINE (benz-a-tro-peen)

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

Drugs used for the treatment of pain Simple Analgesics Weak Opioids Strong Opioids Oral Strong Opioids Transdermal Strong Opioids Subcutaneous

Conservative Management of Uraemia

Clinical Guideline for the management of inpatients with Parkinson s disease

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

APPENDIX K Pharmacological Management

Introduction to Drug Treatment

Page 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk

Pharmacologic Interventions for. Addictions

4: Central Nervous System

Smoking Cessation Pharmacotherapy Guidelines

Supportive Care. End of Life Phase

Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care

Buprenorphine pharmacology

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Common medicines given to neurology patients on discharge from hospital

Joint Formulary for Psychotropic Medication.

NSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present.

This document has been produced in collaboration with the Lancashire Commissioning Support Unit

Part ONE Answer ALL questions. Write the correct answer CLEARLY in the answer grid provided.

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth

POLICY DOCUMENT. CG/pain management in opioid dependency/03/15. Associate Director of Pharmacy

Management of headache

Updated advice for nurses who care for patients with epilepsy

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

10th Medicine Review Course st July Prakash Kumar

Commonly encountered medications and their side effects - what the generalist needs to know

On completion of this chapter you should be able to: list the most common types of childhood epilepsies and their symptoms

SMOKING AND DRUG INTERACTIONS

Medications used to treat Parkinson s disease

TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER)

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse

Algorithms for Symptom Management. In End of Life Care

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP

C AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS

Nervous System. Chapter 4 TABLE OF CONTENTS

INDEX. Index. in this web service Cambridge University Press

EPILEPSY DIAGNOSIS. Investigations- EEG, MRI, CT, blood tests. Appendix 1 contains a guide to questions to help with diagnosis

West London Mental Health NHS Trust Formulary

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

Pain. Christine Illingworth. Community Nurse St Luke s Hospice 17/5/17

Communicating About OFF Episodes With Your Doctor

LL/PLIKI/CENNIK_WYDANIE_SIERPIEN_2016_1

survey Parenteral anti-epileptics What is your experience? May July 2015

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

West London Mental Health NHS Trust Formulary

Practical Management Of Osteoporosis

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

An Overview of Parkinson s Medication used in Multiple System Atrophy

Analgesia in patients with impaired renal function Formulary Guidance

Enhanced Community Palliative Support Services. Lynne Ghasemi St Luke s Hospice

Costing statement. Implementing NICE guidance. January NICE clinical guideline 137

Biological Addictions Treatment. Psychology 470. Many Types of Approaches

CYCLIC VOMITING SYNDROME. C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis

Introduction. 1 person in 20 will have an epileptic seizure at some time in their life

CAMBRIDGESHIRE & PETERBOROUGH STOP SMOKING SERVICE S. Stop Smoking Pharmacological Products Guidance

Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert

Transcription:

Hypnotics Anxiolytics Acute state Non drug treatment Temazepam tablets 10mg, 20mg; oral solution 10mg/5ml or Zolpidem tablets 5mg, 10mg or Zopiclone 3.75mg, 7.5mg Non drug treatment Diazepam tablets 2mg, 5mg, 10mg; oral solution 2mg/5ml Antidepressant drugs for treatment of depression Generalised disorder (GAD), social disorder Panic Disorder Post Traumatic Stress Disorder (PTSD) Obsessive compulsive disorder (OCD) CNS stimulants Narcolepsy For information specialist initiation only CNS stimulants Attention deficit hyperactivity disorder (ADHD) For information specialist initiation only CNS stimulants Attention deficit hyperactivity disorder (ADHD) For information specialist initiation only (Cont.) Citalopram tablets 10mg, 20mg, 40mg; oral drops, citalopram (as hydrochloride) 40mg/ml (4 drops (8mg) is equivalent in therapeutic effect to 10mg tablet) or Fluoxetine capsules 20mg; liquid 20mg/5ml or Sertraline tablets 50mg, 100mg Non pharmacological treatment Sertraline tablets 50mg, 100mg [unlicensed indication] Non pharmacological treatment or Citalopram tablets 10mg, 20mg, 40mg or Sertraline tablets 50mg, 100mg Non pharmacological or Fluoxetine 20mg capsules [unlicensed indication] or Mirtazepine tablets 15mg, 30mg, 45mg [unlicensed indication] Non pharmacological treatment Citalopram tablets 10mg, 20mg, 40mg [unlicensed indication] or Fluoxetine capsules 20mg; liquid 20mg/5ml or Sertraline tablets 50mg, 100mg Modafinil tablets 100mg Methylphenidate tablets modified release 18mg, 27mg, 36mg, 54mg (Delmosart ) Methylphenidate standard release tablets 5mg, 10mg, 20mg

Obesity NI Formulary: Chapter 4 Central Nervous system Nausea and vomiting Drugs for the short term treatment of nausea and vomiting. For Migraine see 4.7.4 Nausea and vomiting Motion sickness Nausea and vomiting Opioid induced (not palliative care) Labyrinthine vertigo General management of acute pain (i) Non opioid and compound analgesics (For dysmenorrhoea, see NIF Chapter 7) (For musculoskeletal and joint pain, including gout, see NIF Chapter 10) (For migraine, see NIF 4.7.4) General management of acute pain (ii) Opioid analgesics Non pharmacological treatment diet and lifestyle changes Orlistat capsules 120mg Prochlorperazine tablets 5mg, buccal tablets 3mg (Reserve buccal tablets for active vomiting) or Domperidone tablets 10mg; suspension 5mg/5ml or Metoclopramide tablets 10mg; oral solution 5mg/5ml; injection 5mg/ml Advise patients that medication can be purchased overthe counter (OTC) Cyclizine tablets 50mg; injection 50mg/ml or Prochlorperazine tablets 5mg; syrup 5mg/ml; buccal tablets 3mg; injection 12.5mg/ml Cinnarizine tablets 15mg or Prochlorperazine tablets 5mg; syrup 5mg/ml Paracetamol tablets 500mg Co codamol 8/500 tablets (codeine 8mg with Co codamol 30/500 tablets (codeine 30mg with Morphine Morphine immediate release tablets 10mg, 20mg 50mg; oral solution 10mg/5ml; 100mg/5ml; modified release tablets, capsules; injection (see BNF) (Prescribe by brand) Chronic non malignant pain Paracetamol tablets 500mg Co codamol 8/500 tablets (codeine 8mg with Co codamol 15/500 tablets (codeine 15mg with Co codamol 30/500 tablets (codeine 30mg with +/- NSAID (see NIF 10.1)

Chronic non malignant pain (cont..) Neuropathic pain (except trigeminal neuralgia) Acute migraine Treatment of acute attack Migraine prophylaxis If pain not resolved in 6 weeks consider Modified Release Preparations Tramadol modified release, m/r tablets 50mg, 100mg, 150mg, 200mg; m/r capsules 50mg, 100mg, 150mg, 200mg (Maxitram ) +/ NSAID / Paracetamol or Buprenorphine patch (as a sole agent) Butec patches, 5 patch (releasing 5 micrograms/ hour), 10 patch (releasing 10 micrograms/hour), 20 patch (releasing 20 micrograms/hour) Morphine MR modified release 12 hourly tablets, capsules (see BNF) Fentanyl patches, 12 patch (releasing approx. 12 micrograms/hour for 72 hours), 25 patch, 37.5 patch (Mezolar ) Amitriptyline tablets 10mg, 25mg, 50mg; oral solution 25mg/5ml, 50mg/5ml [unlicensed] or Gabapentin capsules 100mg, 300mg, 400mg Duloxetine capsules 30mg, 60mg or Pregabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg Ibuprofen tablets 200mg, 400mg, 600mg or Paracetamol tablets 500mg Plus oral triptan: Sumatriptan tablets 50mg, 100mg Almotriptan tablets 12.5mg Propranolol tablets 10mg, 40mg, 80mg, 160mg Propranolol m/r 80mg, 160mg Topiramate tablets 25mg, 50mg, 100mg Cluster headache Acute attacks Sumatriptan subcutaneous injection 6mg/0.5ml syringe Cluster headache Prophylaxis Verapamil tablets 40mg, 80mg, 120mg, 160mg [unlicensed indication] [under specialist supervision] Control of epilepsy Pharmacological treatment of focal (partial) seizures, with or without secondary generalization If pain still not adequately controlled consider morphine MR Carbamazepine m/r tablets 200mg, 400mg Carbamazepine tablets 100mg, 200mg, 400mg; liquid 100mg/5ml Carbamazepine suppositories 125mg, 250mg Or Lamotrigine tablets 25mg, 50mg, 100mg, 200mg

Control of epilepsy Pharmacological treatment of focal (partial) seizures, with or without secondary generalization (Cont..) Control of epilepsy Pharmacological treatment of generalised (primary generalized tonic clonic, absence, myoclonic, tonic, clonic, atonic) and unclassified seizures Levetiracetam tablets f/c 250mg, 500mg, 750mg, 1g; oral solution 100mg/ml Or Oxcarbazepine tablets 150mg, 300mg, 600mg Or Sodium valproate tablets e/c 200mg, 500mg; m/r 200mg, 300mg, 500mg; oral solution 200mg/5ml [NB Sodium valproate not recommended for women and girls of present and future childbearing potential] Sodium valproate tablets e/c 200mg, 500mg; m/r 200mg, 300mg, 500mg; oral solution 200mg/5ml; liquid 200mg/5ml; syrup 200mg/5ml; injection 100mg/ml; intravenous injection 400mg [NB Sodium valproate not recommended for women and girls of present and future childbearing potential] or Lamotrigine tablets 25mg, 50mg, 100mg, 200mg Drugs used in status epilepticus Levetiracetam tablets f/c 250mg, 500mg, 750mg, 1g; oral solution 100mg/ml ; concentrate for intravenous infusion 100mg/ml Or Topiramate tablets 25mg, 50mg, 100mg, 200mg Step 1 (in community) Midazolam buccal liquid Prescribe by brand Diazepam rectal solution 10mg/2.5ml Step 2 (in hospital) Lorazepam injection 4mg/ml Or Diazepam injection (emulsion) 5mg/ml (Diazemuls ) Or Midazolam buccal liquid NB. To be used only when IV access not available Step 3 (In hospital) Fosphenytoin sodium N.B. prescriptions for fosphenytoin sodium should state the dose in terms of phenytoin sodium equivalent (PE), fosphenytoin sodium 1.5mg Ξ phenytoin sodium 1mg Or Phenytoin sodium injection 50mg/ml Phenobarbital (phenobarbitone) injection 200mg/ml

Dopamine receptor agonists Ropinirole tablets 250 micrograms, 1mg, 2mg, 5mg; Ropinirole tablets m/r 2mg, 4mg, 8mg or Pramipexole tablets 88 micrograms base (125 micrograms salt), 180micrograms base (250 micrograms salt), 350micrograms base (500micrograms salt), 700micrograms base (1mg salt); pramipexole tablets m/r 260micrograms, 520 micrograms, 1.05mg, 1.57mg, 2.1mg, 2.62mg, 3.15mg (See BNF for equivalent strengths in terms of pramipexole dihydrochloride monohydrate salt) Levodopa Monoamine oxidase B (MAOB) inhibitors Dopamine enzyme inhibitors / catechol O methyltransferase inhibitors (COMT inhibitors) Co beneldopa (Madopar ) containing levodopa and benserazide Or Co careldopa (Sinemet ) containing levodopa and carbidopa Rasagiline tablets 1mg Or Selegiline tablets 5mg, 10mg; oral lyophilisate 1.25mg Entacapone tablets 200mg Tolcapone 100mg tablets Antimuscarinic drugs used in Procyclidine tablets 5mg or Trihexyphenidyl hydrochloride tablets 2mg, 5mg Intractable hiccups Chlorpromazine tablets 25mg, 50mg; oral solution 25mg/5ml Essential tremor or tremors associated with or thyrotoxicosis Management of dementia in Parkinson s disease Drugs used in substance dependence Opioid maintenance prescribing Propranolol tablets 10mg, 40mg, 80mg, 160mg, capsules m/r 80mg, 160mg Non drug treatment see Prescribing Notes Rivastigmine capsules 1.5mg, 3mg, 4.5mg, 6mg; oral solution 2mg/ml For information only: Usual drugs prescribed for substitute prescribing Buprenorphine sublingual tablets 400micrograms, 2mg, 8mg or Suboxone (sublingual) buprenorphine 2mg/naloxone 500micrograms tablets, buprenorphine 8mg/naloxone 2mg tablets (Reserve Suboxone for when there is a risk of dose diversion for parenteral administration) or Methadone oral solution 1mg/ml

Benzodiazepines addiction and withdrawal Alcohol dependance Assisted alcohol withdrawal for moderate to severe alcohol dependence Alcohol dependance Relapse Prevention Diazepam tablets 2mg, 5mg, 10mg Chlordiazepoxide capsules 5mg, 10mg; tablets 10mg AND psychosocial support Or In patient only if withdrawal seisures occur: Diazepam emulsion injection 5ml/ml (Diazemuls ) AND psychosocial support Acamprosate (Campral EC ) tablets e/c 333mg AND a psychological intervention, e.g. CBT, behavioural therapies, social network and environment based therapies, or behavioural couples therapy or Naltrexone tablets 50mg (initiated under specialist advice) AND a psychological intervention [unlicensed indication] On specialist advice Disulfiram tablets 200mg AND a psychological intervention On specialist advice Alcohol Dependance vitamin supplementation Oral Prophylaxis Alcohol dependance Vitamin supplementation Parenteral Prophylaxis Low risk of Wernicke s Encephaopathy (WE) Thiamine (vitamin B1) tablets 100mg Parenteral vitamins B and C (Pabrinex ) Intramuscular High Potency injection Or Parenteral vitamins B and C (Pabrinex ) Intravenous High Potency injection Refer to section 4.10d of NIF website for dosage information Cigarette smoking Behavioural support + nicotine replacement therapy (long acting) patch 5mg, 10mg, 15mg or 25mg over 16 hours, 7mg, 14mg or 21mg over 24 hours or Behavioural support + nicotine replacement therapy (short acting) gum, lozenge, sublingual tablet, mouth spray, nasal spray, inhalator, orodispersible film; nicotine chewing gum 2mg, 4mg, 6mg; nicotine lozenges 1mg, 1.5mg, 2mg, 4mg, sublingual nicotine tablets 2mg, nicotine mouth spray 1mg/spray, nicotine nasal spray 500micrograms/spray, nicotine inhalator 15mg/cartridge, nicotine 2.5mg orodispersible film

Cigarette smoking (cont ) Varenicline f/c tablets 500 micrograms, 1mg ❸ Bupropion hydrochloride 150mg m/r, f/c tablets Donepezil tablets 5mg, 10mg; orodispersible tablets 5mg, 10mg Drugs for dementia Mild to moderate dementia in Alzheimer's disease Galantamine m/r capsules 8mg, 16mg, 24mg or Rivastigmine capsules 1.5mg, 3mg, 4.5mg, 6mg; patch 4.6mg/24 hours and 9.5mg/24 hours Drugs for dementia Moderate to severe dementia in Alzheimer's disease or moderate dementia in Alzheimer s disease for people who cannot take AchE inhibitors Alzheimer s disease Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Memantine tablets 10mg, 20mg; treatment initiation pack 7x5mg, 7x10mg, 7x15mg and 7x20mg; oral drops 5mg/actuation Non drug treatment / watchful waiting Risperidone tablets 500micrograms, 1mg; liquid 1mg/ml